Whilst there are currently no treatments that can delay the onset or prevent the progression of genetic FTD, there are promising avenues for treatment, particularly for GRN mutations where a uniform disease mechanism of loss of progranulin function operates in all mutation carriers. This evidence concerns the gene GRN and frontotemporal dementia.